JP6576355B2 - 細胞輸送 - Google Patents
細胞輸送 Download PDFInfo
- Publication number
- JP6576355B2 JP6576355B2 JP2016549646A JP2016549646A JP6576355B2 JP 6576355 B2 JP6576355 B2 JP 6576355B2 JP 2016549646 A JP2016549646 A JP 2016549646A JP 2016549646 A JP2016549646 A JP 2016549646A JP 6576355 B2 JP6576355 B2 JP 6576355B2
- Authority
- JP
- Japan
- Prior art keywords
- cpp
- molecule
- therapeutic agent
- cupid
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1318954.3 | 2013-10-28 | ||
| GBGB1318954.3A GB201318954D0 (en) | 2013-10-28 | 2013-10-28 | Cell transport |
| PCT/GB2014/053037 WO2015063452A2 (en) | 2013-10-28 | 2014-10-09 | Cell transport |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016535600A JP2016535600A (ja) | 2016-11-17 |
| JP2016535600A5 JP2016535600A5 (enExample) | 2017-11-09 |
| JP6576355B2 true JP6576355B2 (ja) | 2019-09-18 |
Family
ID=49767211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549646A Active JP6576355B2 (ja) | 2013-10-28 | 2014-10-09 | 細胞輸送 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9913914B2 (enExample) |
| EP (1) | EP3062822B1 (enExample) |
| JP (1) | JP6576355B2 (enExample) |
| CA (1) | CA2928773A1 (enExample) |
| GB (1) | GB201318954D0 (enExample) |
| WO (1) | WO2015063452A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11965004B2 (en) * | 2017-07-10 | 2024-04-23 | Sri International | Molecular guide system peptides and uses thereof |
| CN112423781A (zh) | 2018-07-13 | 2021-02-26 | 普林斯顿大学理事会 | 用于调节应激颗粒组装的系统和方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5523359A (en) * | 1995-01-13 | 1996-06-04 | Exxon Chemical Patents Inc. | Functionalized polymer and methods to obtain functionalized polymer |
| GB9814527D0 (en) * | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
| IL142869A0 (en) | 1998-11-13 | 2002-03-10 | Cyclacel Ltd | Transport vectors |
| US7091026B2 (en) | 2001-02-16 | 2006-08-15 | University Of Iowa Research Foundation | Artificial endonuclease |
| GB0229151D0 (en) * | 2002-12-13 | 2003-01-15 | St Georges Entpr Ltd | Product and method |
| WO2005016387A2 (en) | 2003-08-12 | 2005-02-24 | University Of Iowa Research Foundation | Dna-dependent mri contrast agents |
| US20100168034A1 (en) * | 2006-02-20 | 2010-07-01 | Ewha University-Industry Collaboration Foundation | Peptide having cell membrane penetrating activity |
| WO2007109908A1 (en) * | 2006-03-29 | 2007-10-04 | The University Of British Columbia | Therapeutic yb-1 phosphorylation decoys |
| WO2012023284A1 (en) | 2010-08-20 | 2012-02-23 | Oncotherapy Science, Inc. | Lhx4 as a target gene for cancer therapy and diagnosis |
| WO2012170431A2 (en) | 2011-06-06 | 2012-12-13 | Bluebird Bio, Inc. | Improved geneswitch systems |
-
2013
- 2013-10-28 GB GBGB1318954.3A patent/GB201318954D0/en not_active Ceased
-
2014
- 2014-10-09 EP EP14784358.5A patent/EP3062822B1/en active Active
- 2014-10-09 US US15/032,668 patent/US9913914B2/en active Active
- 2014-10-09 WO PCT/GB2014/053037 patent/WO2015063452A2/en not_active Ceased
- 2014-10-09 JP JP2016549646A patent/JP6576355B2/ja active Active
- 2014-10-09 CA CA2928773A patent/CA2928773A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3062822A2 (en) | 2016-09-07 |
| US20160310607A1 (en) | 2016-10-27 |
| EP3062822B1 (en) | 2025-05-14 |
| EP3062822C0 (en) | 2025-05-14 |
| WO2015063452A2 (en) | 2015-05-07 |
| WO2015063452A3 (en) | 2015-09-17 |
| JP2016535600A (ja) | 2016-11-17 |
| CA2928773A1 (en) | 2015-05-07 |
| US9913914B2 (en) | 2018-03-13 |
| GB201318954D0 (en) | 2013-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapy | |
| US10688194B2 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
| US10421784B2 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
| US10118944B2 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
| US10131888B2 (en) | Intracellular protein delivery | |
| EP2891661B1 (en) | Mitochondrial targeting peptide | |
| US20140051646A1 (en) | Cell penetrating peptides | |
| US9969774B2 (en) | Cell penetrating peptide and method for delivering biologically active substance using same | |
| US20160115199A1 (en) | Cell Penetrating Peptides for Intracellular Delivery of Molecules | |
| JP2010154842A (ja) | Egfrを標的にした新規抗がんキメラペプチド | |
| WO2012137036A1 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
| KR101778244B1 (ko) | 세포 투과성 펩티드 및 이를 이용한 생물학적 활성 물질의 전달방법 | |
| US11834517B2 (en) | Branched peptides for enzymatic assembly and mitochondria drug delivery | |
| JP6576355B2 (ja) | 細胞輸送 | |
| JP2020536582A (ja) | 遺伝子発現抑制剤 | |
| Zhang et al. | Stearylated antimicrobial peptide [D]-K6L9 with cell penetrating property for efficient gene transfer | |
| JP5700409B2 (ja) | Hsp90を標的にした新規抗がんキメラペプチド | |
| CN109790225B (zh) | 用于靶向dsRNA的嵌合蛋白 | |
| Cahill | Cell-penetrating peptides, electroporation and drug delivery | |
| US20240158441A1 (en) | Branched peptides for enzymatic assembly and mitochondria drug delivery | |
| Marchione et al. | Study on the internalization mechanism of the ZEBRA cell-penetrating peptide | |
| WO2024156871A1 (en) | Mixtures of lipid nanoparticles and cell penetrating peptides | |
| WO2024075767A1 (ja) | ミトコンドリアへの核酸の導入方法 | |
| JP2025504832A (ja) | CD32aに特異的な結合タンパク質 | |
| JP2023542341A (ja) | 標的化された抗原送達システム及びその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170929 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170929 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180720 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180803 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181102 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190215 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190612 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190612 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190701 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190802 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190820 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6576355 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |